Gisbert Javier P, García-Buey Luisa, Arranz Reyes, Blas Carlos, Pinilla Inmaculada, Khorrami Sam, Acevedo Agustín, Borque María J, Pajares José M, Fernández-Rañada José M, Moreno-Otero Ricardo
Gastroenterology and Hepatology Service, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Spain.
Eur J Gastroenterol Hepatol. 2004 Feb;16(2):135-8. doi: 10.1097/00042737-200402000-00003.
Lymphomagenesis is a multifactorial process in which genetic, environmental and infectious factors can be involved. The aim of the present study was to assess the prevalence of hepatitis C virus (HCV) infection among patients with non-Hodgkin's lymphoma (NHL), and to compare it with that of a control group of voluntary blood donors.
All consecutive patients with a histological diagnosis of NHL from January 1996 to December 2001 were included in this prospective study. As control group for HCV infection, voluntary blood donors recruited over the same time period from the same geographical area were considered. The presence of anti-HCV antibodies was investigated by ELISA-II and RIBA-II, and viraemia (HCV RNA) was tested by using a polymerase chain reaction (PCR). HCV genotyping was also performed.
Ninety-nine patients (mean age 48 years) with NHL were diagnosed during the study period. Histological classification of NHL was high-intermediate grade (63 patients), and low grade (36 patients). Immunophenotype distribution was type B (86 patients) and type T (13 patients). Seven of the 99 NHL patients (7%) were infected with HCV (both using serology and PCR), five of them with immunophenotype B and two with immunophenotype T. The prevalence of HCV infection according to NHL phenotype was 5.8% in B-cell NHL and 15.4% in T-cell NHL. The HCV genotype was 1b in six cases, and 3a in one. In voluntary blood donors (mean age 45 years), HCV infection was detected in 517/55 587 (0.93%). Therefore, HCV infection was more frequent in NHL patients than in controls (odds ratio = 8.1; 95% CI = 3.7-17.6). The odds ratio for the association of HCV and B-cell NHL was 6.2 (95% CI = 2.5-15.3), and for T-cell NHL 16.4 (95% CI = 3.7-72.8).
The prevalence of HCV infection in patients with NHL (both B- and T-type) is higher than that observed in controls, suggesting a role of HCV in lymphoma aetiopathogenesis.
淋巴瘤的发生是一个多因素过程，可能涉及遗传、环境和感染因素。本研究的目的是评估丙型肝炎病毒（HCV）在非霍奇金淋巴瘤（NHL）患者中的感染率，并将其与一组自愿献血者对照组进行比较。
本前瞻性研究纳入了1996年1月至2001年12月间所有经组织学诊断为NHL的连续患者。作为HCV感染的对照组，考虑同期从同一地理区域招募的自愿献血者。通过ELISA-II和RIBA-II检测抗HCV抗体的存在，并使用聚合酶链反应（PCR）检测病毒血症（HCV RNA）。还进行了HCV基因分型。
在研究期间诊断出99例NHL患者（平均年龄48岁）。NHL的组织学分类为高中级（63例）和低级（36例）。免疫表型分布为B型（86例）和T型（13例）。99例NHL患者中有7例（7%）感染了HCV（血清学和PCR检测均为阳性），其中5例为免疫表型B，2例为免疫表型T。根据NHL表型，HCV感染率在B细胞NHL中为5.8%，在T细胞NHL中为15.4%。HCV基因型6例为1b型，1例为3a型。在自愿献血者（平均年龄45岁）中，517/55587（0.93%）检测到HCV感染。因此，NHL患者中HCV感染比对照组更常见（优势比=8.1；95%可信区间=3.7-17.6）。HCV与B细胞NHL关联的优势比为6.2（95%可信区间=2.5-15.3），与T细胞NHL关联的优势比为16.4（95%可信区间=3.7-72.8）。
NHL患者（B型和T型）中HCV感染率高于对照组，提示HCV在淋巴瘤发病机制中起作用。
